{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:19Z","timestamp":1791920899231,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cmi.2024.10.001","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:21:14Z","timestamp":1728505274000},"page":"931-940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preclinical and clinical studies in the drug development process of European Medicines Agency-approved non-HIV antiviral agents: a narrative review"],"prefix":"10.1016","volume":"31","author":[{"given":"Lena","family":"Pracher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.10.001_bib1","series-title":"WHO coronavirus (COVID-19) dashboard","year":"2023"},{"key":"10.1016\/j.cmi.2024.10.001_bib2","series-title":"History of EMA","year":"2023"},{"key":"10.1016\/j.cmi.2024.10.001_bib3","series-title":"Authorisation of medicines","year":"2023"},{"key":"10.1016\/j.cmi.2024.10.001_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s43441-023-00574-6","article-title":"Comparison between European Medicines Agency and US Food and Drug Administration in granting accelerated marketing authorizations for Covid-19 medicines and their utilized regulations","volume":"58","author":"Ghadanian","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.cmi.2024.10.001_bib5","series-title":"Conditional marketing authorisation","year":"2023"},{"key":"10.1016\/j.cmi.2024.10.001_bib6","series-title":"European public assessment reports: background and context [Internet]","year":"2023"},{"key":"10.1016\/j.cmi.2024.10.001_bib7","series-title":"Scientific guidelines","year":"2023"},{"key":"10.1016\/j.cmi.2024.10.001_bib8","series-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products (EMA\/CHMP\/594085\/2015)","year":"2016"},{"key":"10.1016\/j.cmi.2024.10.001_bib9","series-title":"Guidance for industry: Antiviral product development\u2014conducting and submitting virology studies to the Agency (FDA-2005-D-0282)","year":"2006"},{"key":"10.1016\/j.cmi.2024.10.001_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it\u2019s not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.001_bib11","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/pharmaceutics15041212","article-title":"ADME, pharmacokinetic scaling, pharmacodynamic and prediction of human dose and regimen of novel antiviral drugs","volume":"15","author":"Chaira","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cmi.2024.10.001_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.coph.2008.06.010","article-title":"PK\/PD: new insights for antibacterial and antiviral applications","volume":"8","author":"Schmidt","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.cmi.2024.10.001_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018320","article-title":"Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov","volume":"8","author":"Bothwell","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2024.10.001_bib14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.coviro.2012.09.013","article-title":"Hepatitis C virus-host interactions, replication, and viral assembly","volume":"2","author":"Shulla","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.cmi.2024.10.001_bib15","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.chom.2014.10.009","article-title":"The impact of hepatitis C virus entry on viral tropism","volume":"16","author":"Ding","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cmi.2024.10.001_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00430-007-0073-y","article-title":"Rhesus CMV: an emerging animal model for human CMV","volume":"197","author":"Powers","year":"2008","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.cmi.2024.10.001_bib17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40262-020-00892-0","article-title":"Preclinical pharmacokinetic\/pharmacodynamic studies and clinical trials in the drug development process of EMA-approved antibacterial agents: a review","volume":"59","author":"Jorda","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2024.10.001_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40262-023-01327-2","article-title":"Preclinical pharmacokinetic\/pharmacodynamic studies and clinical trials in the drug development process of EMA-approved antifungal agents: a review","volume":"63","author":"Pecho","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2024.10.001_bib19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0168-8278(99)80118-4","article-title":"Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients","volume":"30","author":"Locarnini","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.cmi.2024.10.001_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","article-title":"Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond","volume":"155","author":"Chaudhuri","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.cmi.2024.10.001_bib21","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s12072-022-10402-y","article-title":"Drug\u2013drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study","volume":"16","author":"Hui","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cmi.2024.10.001_bib22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/cid\/civ973","article-title":"Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort","volume":"62","author":"H\u00f6ner Zu Siederdissen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.001_bib23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","article-title":"Drug\u2013drug interactions during antiviral therapy for chronic hepatitis C","volume":"10","author":"Kiser","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2024.10.001_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1034\/j.1600-0676.2001.021004260.x","article-title":"Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis","volume":"21","author":"Herold","year":"2001","journal-title":"B C Liver"},{"key":"10.1016\/j.cmi.2024.10.001_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","article-title":"Liver disease selectively modulates cytochrome P450\u2013mediated metabolism","volume":"80","author":"Frye","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2024.10.001_bib26","first-page":"678a","article-title":"Alteration of the portal circulation across the entire spectrum of fibrosis in patients with chronic hepatitis C as measured by dual cholate clearances [abstract 1005]","volume":"56","author":"Helmke","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2024.10.001_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2017.09.004","article-title":"In vivo infection models in the preclinical pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents","volume":"36","author":"Andes","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.cmi.2024.10.001_bib28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-023-00692-8","article-title":"Accelerating antiviral drug discovery: lessons from COVID-19","volume":"22","author":"von Delft","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cmi.2024.10.001_bib29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intens Care Med"},{"key":"10.1016\/j.cmi.2024.10.001_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1281","article-title":"Hepatitis B treatment: what we know now and what remains to be researched","volume":"3","author":"Suk-Fong Lok","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cmi.2024.10.001_bib32","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2024.10.001_bib33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/hep4.1875","article-title":"Aiming for functional cure with established and novel therapies for chronic hepatitis B","volume":"6","author":"Choi","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cmi.2024.10.001_bib34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.gastro.2022.10.008","article-title":"Current best practice in hepatitis B management and understanding long-term prospects for cure","volume":"164","author":"Yardeni","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2024.10.001_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","article-title":"Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives","volume":"36","author":"Asselah","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cmi.2024.10.001_bib36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejmech.2019.01.025","article-title":"Hepatitis C \u2013 new drugs and treatment prospects","volume":"165","author":"Zaj\u0105c","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cmi.2024.10.001_bib37","article-title":"Price of a hepatitis C cure: cost of production and current prices for direct-acting antivirals in 50 countries","volume":"6","author":"Barber","year":"2020","journal-title":"J Virus Erad"},{"key":"10.1016\/j.cmi.2024.10.001_bib38","series-title":"Public summary of opinion on orphan designation: synthetic 47-amino-acid N-myristoylated lipopeptide, derived from the preS region of hepatitis B virus for the treatment of hepatitis delta virus infection (EMA\/COMP\/360280\/2015)","year":"2015"},{"key":"10.1016\/j.cmi.2024.10.001_bib39","unstructured":"Gilead Sciences. Gilead receives complete response letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus 2022. [Internet]. Published 2022 October 27 [cited 2024 April 23]. Available from: https:\/\/www.gilead.com\/company\/company-statements\/2022\/gilead-receives-complete-response-letter-from-us-fda-for-bulevirtide-for-the-treatment-of-adults-with-hepatitis-delta-virus"},{"key":"10.1016\/j.cmi.2024.10.001_bib40","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","volume":"12","author":"El","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2024.10.001_bib41","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.10.001_bib42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/QCO.0000000000000983","article-title":"A new direction for cytomegalovirus prophylaxis among transplant recipients: benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis","volume":"36","author":"Moore","year":"2023","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.001_bib43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/cid\/ciaa1713","article-title":"Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients","volume":"73","author":"Imlay","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.001_bib44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.001_bib45","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial clinical infectious diseases","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.001_bib46","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.001_bib47","first-page":"884","article-title":"What\u2019s new: updates on cytomegalovirus in solid organ transplantation","volume":"108","author":"Stewart","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2024.10.001_bib48","series-title":"Smallpox","year":"2024"},{"key":"10.1016\/j.cmi.2024.10.001_bib49","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1126\/science.283.5406.1279","article-title":"The looming threat of bioterrorism","volume":"283","author":"Henderson","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.cmi.2024.10.001_bib50","series-title":"Product development under the animal rule: guidance for industry (FDA-2009-D-0007)","year":"2015"},{"key":"10.1016\/j.cmi.2024.10.001_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral tecovirimat for the treatment of smallpox","volume":"379","author":"Grosenbach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.10.001_bib52","series-title":"EU risk management plan for tecovirimat SIGA (tecovirimat monohydrate); Version 1.7","year":"2023"},{"key":"10.1016\/j.cmi.2024.10.001_bib53","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2024.10.001_bib54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/phe\/phv026","article-title":"Ethical criteria for human challenge studies in infectious diseases","volume":"9","author":"Bambery","year":"2016","journal-title":"Public Health Ethics"},{"key":"10.1016\/j.cmi.2024.10.001_bib55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7573\/dic.2020-4-14","article-title":"The journey of remdesivir: from Ebola to COVID-19","volume":"9","author":"Pardo","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.cmi.2024.10.001_bib56","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/acscentsci.3c00145","article-title":"Development of the commercial manufacturing process for nirmatrelvir in 17 months","volume":"9","author":"Allais","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.cmi.2024.10.001_bib57","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41591-022-01945-6","article-title":"A lightspeed approach to pandemic drug development","volume":"28","author":"Anderson","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2024.10.001_bib58","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T20:20:13Z","timestamp":1746908413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24004804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1198743X24004804"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.10.001","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical and clinical studies in the drug development process of European Medicines Agency-approved non-HIV antiviral agents: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}